Dispensary Weed Is a Different Drug Than the One D.A.R.E. Warned You About

A woman turns a milestone age. A husband, a Colorado dispensary, a legal purchase, a plan to relive something she remembered fondly from decades earlier. That’s the setup she wrote about for CNN — and the punchline wasn’t a nice buzz. It was spending her birthday night hugging the toilet instead of enjoying it, because the product she bought bore almost no relationship, milligram for milligram, to whatever she’d smoked in her twenties. She’d expected a mellow evening. She got proof that the drug had changed underneath her.

That’s not a cautionary tale about one bad night. It’s the data.

Weak weed was never the danger. What’s sold legally now, at strengths nobody sold thirty years ago, might be — and almost nobody selling it has to say so.

She Remembered a Different Drug, Because It Was One

The cannabis sold at a licensed Colorado dispensary in 2026 isn’t a stronger version of what was around in the 1990s — it’s closer to a different substance wearing the same name. THC, the compound that actually gets a person high, has been tracked in seized and monitored U.S. samples since the early 1970s by a federal potency-monitoring program run out of the University of Mississippi. Its numbers, reported by the National Institute on Drug Abuse, show average THC concentration climbing from 3.96% in 1995 to 16.14% in 2022 — roughly a fourfold jump in under three decades. That’s just the average. Dispensary flower today commonly tests above 20%, and concentrates — wax, shatter, vape cartridges — regularly clear 40% THC, sometimes 60% or more.

Put that in terms a person who last smoked in college can use: if you remember a joint getting you pleasantly stupid for an hour, the same-sized joint today is delivering something like four times the active drug. A dab of concentrate can deliver ten times that or more in a single hit. The plant looks the same in the jar. It is not the same drug going into your lungs.

Four Times, Five Times, and the Asterisk That Matters

The obvious question is whether that jump actually does anything to people, beyond getting them higher faster. The best answer from the addiction and psychosis science so far: yes, and the effect isn’t small — but the evidence has real limits, and pretending otherwise does nobody favors.

In 2022, a University of Bath team led by researcher Kat Petrilli published the first systematic review in The Lancet Psychiatry comparing higher-potency and lower-potency cannabis use against psychosis — a break from shared reality involving hallucinations, paranoia, or delusions — and cannabis use disorder (CUD), the clinical term for cannabis use that’s stopped being a choice and started running someone’s life. Across 20 studies and nearly 120,000 participants, daily users of higher-potency cannabis were about five times more likely to be diagnosed with a psychotic disorder than people who’d never used, versus roughly two times higher odds for daily lower-potency users — a pattern a separate 17-site European replication found again. On the addiction side, one UK sample found higher-potency users four times more likely to report recent cannabis problems than lower-potency users; a Japanese clinical sample found seven times the risk of diagnosed dependence.

Those numbers aren’t hedge-everything academic mush — Freeman, the review’s senior author, told reporters plainly that people who use cannabis could cut their risk of harm by choosing lower-potency products. But here’s what gets dropped when this study gets recycled into a headline: not one of the 20 studies was rated “good quality” in the researchers’ own bias assessment — all were “fair” or “poor,” mostly because they relied on people self-reporting what strength they’d used, which is a guess dressed up as data. Most were cross-sectional snapshots that can’t rule out the reverse story — that people already prone to psychosis or anxiety reach for stronger products, not that the products cause it. And the review’s own authors flagged that people partially compensate for stronger cannabis by using less of it, which would shrink these associations rather than inflate them — meaning potency’s true effect could be smaller than these numbers suggest, not larger.

A newer, much larger review reinforces the direction without resolving the uncertainty. In September 2025, a team led by Thanitsara Rittiphairoj at the University of Colorado Anschutz Medical Campus published a review in Annals of Internal Medicine screening 99 studies and roughly 221,000 participants spanning 1977 to 2023, comparing high-concentration THC products — defined across studies as more than 5 milligrams of THC per serving, more than 10% THC, or products marketed as concentrate, shatter, or dab — against lower-strength cannabis. It found consistent associations with psychosis, schizophrenia, and CUD, and no evidence high-potency products offered any therapeutic upside. The researchers were blunt about what they hadn’t proven, concluding the evidence “fall[s] short of providing the definitive evidence needed to provide clear advice to patients” and calling for better-designed studies rather than declaring the case closed. Findings on anxiety and depression were mixed and weaker than the psychosis and CUD signal.

It found consistent associations with psychosis, schizophrenia, and CUD, and no evidence high-potency products offered any therapeutic upside.

We’ve Run This Panic Before, Aimed at the Wrong Drug

Here’s the reversal worth sitting with. In 1983, LAPD Chief Daryl Gates and L.A. schools chief Harry Handler launched D.A.R.E. — Drug Abuse Resistance Education — sending officers into classrooms to warn kids off marijuana as the first domino to hard drugs. It became the biggest drug-prevention program in U.S. history, reaching over 75% of school districts and $750 million a year in federal funding at its peak. Study after study — a 1994 federal meta-analysis, a ten-year study by Donald Lynam in 1999, a 2009 meta-analysis finding its effect on drug use rounded to zero — found it didn’t work. In 2001, the Surgeon General formally classified it an “Ineffective Primary Prevention Program.” The cannabis those kids were warned off averaged under 4% THC. Today’s commercial product routinely tops ten times that.

The panic landed on the mild version of the drug and mostly missed. Now the industry sells something genuinely more potent than anything that existed in the D.A.R.E. era, marketed with none of that alarm — and, since May 2025, with even less federal capacity to track it: the Trump administration’s DOGE initiative canceled the $143,000 federal contract that funded the University of Mississippi’s decades-old potency-monitoring program — the same program behind the 3.96%-to-16.14% number this piece is built on. The lab that told us how much stronger this got no longer has federal funding to keep counting.

What Nobody at the Counter Is Required to Tell You

If you’re using cannabis now, or thinking about it, here’s the honest version: this isn’t reefer madness, and it isn’t nothing. You don’t need to swear off a plant to want basic information about the dose you’re putting in your body — and right now, in most legal markets, that information stops at a THC percentage on a label, with no counseling requirement, no mandated conversation about tolerance or titration, and nothing that flags for a new or returning user that 30% flower is not the product they remember. If you’ve got a personal or family history of psychosis or schizophrenia, that’s specifically the group the strongest evidence points to — a conversation with a prescriber before regular high-potency use is worth having, not as a scare tactic but as due diligence. If daily concentrate use is creeping into something that feels less like a choice, cannabis use disorder is a real diagnosis with real treatment, not a moral failing you talk yourself out of.

For clinicians and case managers: when you screen for cannabis use, ask about product type and potency, not just frequency — “how often” misses the person doing one high-THC dab a day, which the evidence above suggests carries more risk than five puffs of low-potency flower a week. That single added question costs nothing and catches what “how many times a week” does not.

The dispensary label still tells you the THC percentage — read it. That’s the one piece of real information the current system reliably hands you, and it’s worth using while you have it.

The kids in D.A.R.E. assemblies were warned about a drug that, potency-wise, barely exists anymore. Their kids are buying the drug nobody warned anyone about at all.